A Multicenter, Randomized, Open-Label Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-Injector for the Subcutaneous Self-Injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 03 Oct 2019
Price : $35 *
At a glance
- Drugs Bimekizumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Registrational
- Sponsors UCB Biopharma
- 30 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 18 Jan 2019 Status changed from not yet recruiting to recruiting.
- 13 Dec 2018 New trial record